SYNCRIP

Across TCGA pan-cancer cohorts, SYNCRIP RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated SYNCRIP data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SYNCRIP RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SYNCRIP expression acts as an unfavorable survival marker, although some lineages such as UCS and OV show a favorable association.

MESO, LIHC, and UCS are the cancer types where SYNCRIP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.234	0.506	<.001	96	view →
LIHC	DFS	Median	All	0.469	0.616	<.001	68	view →
UCS	DFS	Median	IV	0.952	0.367	.001	64	view →
OV	OS	Quartile	III,IV	0.423	0.306	.010	48	view →
ACC	DFS	Median	All	0.428	0.730	<.001	46	view →
SCLC	OS	Tertile	All	0.824	0.572	.001	36	view →
KICH	DFS	Median	II,III,IV	0.571	0.920	.005	32	view →
SARC	OS	Tertile	All	0.620	0.838	<.001	32	view →
KIRC	DFS	Quartile	All	0.877	0.675	.002	26	view →
THYM	OS	Median	All	1.000	0.925	.016	23	view →
READ	OS	Quartile	II,III,IV	0.866	0.360	.010	23	view →
GBM	DFS	Tertile	All	0.452	0.174	<.001	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

SYNCRIP–MESO (OS)

Open the MESO breakdown →